# Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel ® as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults

> **NCT02014727** · PHASE1 · COMPLETED · sponsor: **Institut National de la Santé Et de la Recherche Médicale, France** · enrollment: 66 (actual)

## Conditions studied

- Malaria, Falciparum

## Interventions

- **BIOLOGICAL:** Group A1 : 50µg AMA1-DiCo + Alhydrogel
- **BIOLOGICAL:** Group A2 : 50 µg AMA1-DiCo+ GLA-SE
- **BIOLOGICAL:** Group B2 : Placebo

## Key facts

- **NCT ID:** NCT02014727
- **Lead sponsor:** Institut National de la Santé Et de la Recherche Médicale, France
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2015-03
- **Final completion:** 2015-07
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2025-12-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02014727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02014727, "Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel ® as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02014727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*